Serent portfolio company Raintree announced that it has acquired Yoomi Health, a New York-based leader in AI technologies for rehab therapy organizations. This critical addition to Raintree’s product stack will significantly accelerate the Artificial Intelligence and Machine Learning roadmap for Raintree clients. In addition to a series of strategic investments made over the past two years, the Yoomi acquisition further’s Raintree’s commitment to become the leading AI-centric EMR in rehab therapy.
The Yoomi acquisition paves the way for accelerated delivery of AI products that change the paradigm of how rehab therapy EHRs inherently function. Having recently completed an overhaul of its data infrastructure to be optimized for AI applications, Raintree now welcomes the Yoomi team to its rapidly growing AI Center of Excellence to deliver products designed to transform outcomes for practices and patients.
“We are investing heavily to ensure that Raintree leads the EMR field when it comes to therapy-specific AI tools,” explained Nick Hedges, Raintree CEO. “We are very excited to welcome the Yoomi team to Raintree as our extensive research suggests they are a step ahead of their competitors in terms of the sophistication of their approach.”
“We strongly believe the most critical technology advances defining the future will be based on AI,” said Ben Catania, CEO of Yoomi. “Raintree’s shared vision that AI will free clinicians, patients, and billing teams from the need to perform manual tasks within traditional software makes them the perfect partner. With Yoomi and Raintree working together to deliver an all-inclusive native EHR AI solution, we will reduce the cost per activity for rehab therapy practices.”
“We understand how important it is for clients to have choices when it comes to the current ‘scribe-based’ technologies that are on the market today, and we intend to continue to keep these partnerships active,” explained Sarina Richard, Raintree’s Chief Strategy Officer. “However, we also believe that deeply embedding sophisticated AI-driven workflows within our platform provides enhanced functionalities that are simply not possible via a standalone AI vendor integration.”
With its acquisition of Yoomi Health and investment in platform transformation, Raintree is not only addressing the industry-wide challenges facing rehab therapy practices today—including declining reimbursements and staff attrition—but investing in a future where AI-centric technology continually adapts to support its clients’ success.
Disclaimer:
This publication is for informational purposes only, and nothing contained herein constitutes an offer to sell or a solicitation of an offer to buy any interest in any investment vehicle managed by Serent Capital or any company in which Serent Capital or its affiliates have invested. An offer or solicitation will be made only through a final private placement memorandum, subscription agreement and other related documents with respect to a particular investment opportunity and will be subject to the terms and conditions contained in such documents, including the qualifications necessary to become an investor. Serent Capital does not utilize its website to provide investment or other advice, and nothing contained herein constitutes a comprehensive or complete statement of the matters discussed or the law relating thereto. Information provided reflects Serent Capital’s views as of a particular time and are subject to change without notice. You should obtain relevant and specific professional advice before making any investment decision.
Executive endorsements of Serent Capital are for illustrative purposes, designed to attract business development contacts, and should not be construed as a client or investor testimonial of Serent Capital's investment advisory services. All such endorsements are from current or former portfolio company leadership about Serent Capital’s ability to provide services to their companies. Certain executives are also investors in Serent Capital’s investment vehicle(s), and as such, there is an inherent conflict in that those executives have an incentive to provide favorable reviews of Serent Capital’s business practices for the benefit of the investment vehicles that they hold a personal ownership interest in. Serent Capital has not, directly or indirectly, paid any compensation to such individuals for their endorsements.
Certain information on this Website may contain forward-looking statements, which are subject to risks and uncertainties and speak only as of the date on which they are made. The words “believe”, “expect”, “anticipate”, “optimistic”, “intend”, “aim”, “will” or similar expressions are intended to identify forward-looking statements. Serent Capital undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Past performance is not indicative of future results; no representation is being made that any investment or transaction will or is likely to achieve profits or losses similar to those achieved in the past, or that significant losses will be avoided.
